A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

NCT06229912 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
HOX Gene

Interventions

DRUG: Revumenib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]